Format

Send to

Choose Destination
Front Immunol. 2015 Mar 3;6:91. doi: 10.3389/fimmu.2015.00091. eCollection 2015.

Dendritic cell-based vaccine efficacy: aiming for hot spots.

Author information

1
Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO - FUCA) , Buenos Aires , Argentina.

Abstract

Many approaches for cancer immunotherapy have targeted dendritic cells (DCs), directly or indirectly, for the induction of antitumor immune responses. DC-based vaccines have been developed using a wide variety of ex vivo DC culture conditions, antigen (Ag) source and loading strategies, maturation agents, and routes of vaccination. Adjuvants are used to activate innate immune cells at the vaccine injection site, to promote Ag transport to the draining lymph nodes (LNs) and to model adaptive immune responses. Despite years of effort, the effective induction of strong and durable antitumor T-cell responses in vaccinated patients remains a challenge. The study of vaccine interactions with other immune cells in the LNs and, more recently, in the injection site has opened new doors for understanding antitumor effector T-cell licensing and function. In this review, we will briefly discuss the relevant sites and up-to-date facts regarding possible targets for antitumor vaccine refinement. We will focus on the processes taking place at the injection site, adjuvant combinations and their role in DC-based vaccines, LN homing, and modeling vaccine-induced immune responses capable of controlling tumor growth and generating immune memory.

KEYWORDS:

antitumor T cells; cancer vaccines; dendritic cells; draining lymph nodes; immunotherapy; vaccine injection site

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center